RenovoRx, Inc. (RNXT)
| Market Cap | 36.25M -3.7% |
| Revenue (ttm) | 1.49M +520.4% |
| Net Income | -12.27M |
| EPS | -0.33 |
| Shares Out | 45.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,987 |
| Open | 0.7920 |
| Previous Close | 0.8059 |
| Day's Range | 0.7901 - 0.8330 |
| 52-Week Range | 0.7006 - 1.4500 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 6.91 (+758.71%) |
| Earnings Date | May 14, 2026 |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Financial Performance
In 2025, RenovoRx's revenue was $1.12 million, an increase of 2511.63% compared to the previous year's $43,000. Losses were -$11.17 million, 26.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $6.91, which is an increase of 758.71% from the latest price.
News
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comme...
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
Reports Q1 revenue $563,000, consensus $463,250.
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027.
RenovoRx Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue grew 136% sequentially, driven by rapid expansion to 16 active cancer centers and strong repeat orders. Guidance for 2026 revenue remains $3–$4 million, with a robust pipeline and sufficient cash to fund operations into 2027.
RenovoRx Earnings release: Q1 2026
RenovoRx released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
RenovoRx Quarterly report: Q1 2026
RenovoRx has published its Q1 2026 quarterly earnings report on May 14, 2026.
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Thera...
RenovoRx Slides: Investor presentation
RenovoRx has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
RenovoRx Proxy statement: Proxy filing
RenovoRx filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com...
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx files to sell 8.44M shares of common stock for holders
17:11 EDT RenovoRx (RNXT) files to sell 8.44M shares of common stock for holders
RenovoRx Registration statement: Registration filing
RenovoRx filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer
RenovoRx secures Japanese patent allowance for targeted drug-delivery
RenovoRx (RNXT) announced that the Japan Patent Office has issued a Notice of Allowance for the company’s first Japanese patent application titled “Method and Apparatus for Delivering an Agent Through...
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with...
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More
RenovoRx Earnings Call Transcript: Q4 2025
2025 marked the first full year of commercial revenue, with $1.1 million generated and a strong gross margin. The company targets tripling its active sites to 36 in 2026, expects $3–$4 million in revenue, and is well-funded following a $10 million private placement.
RenovoRx Annual report: Q4 2025
RenovoRx has published its Q4 2025 annual report on March 30, 2026.
RenovoRx Earnings release: Q4 2025
RenovoRx released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipat...
RenovoRx’s TIGeR-PaC Phase III trial surpasses 100 randomized patients
RenovoRx (RNXT) announced that it has achieved a key milestone in its ongoing Phase III TIGeR-PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion…
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for Dr...
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones Company has the funding, business plan, leadership and infras...
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com...